McKesson Corporation (MCK)
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
$907.99-1.45%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
Research Workspace
Put MCK beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Oncology & Multispecialty segment revenue growth: rev +8.0% vs 20.0% target.
View ThesisRevenue growth is slowing — up about 9% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 17%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskMcKesson's growth in the Oncology and Multispecialty segment has to keep compounding to justify the price. Revenue grew 8% year over year, but the latest quarter missed expectations. It trades at 22× P/E versus a peer median of 23×, indicating modest growth expectations. The primary risk is a credibility hit if guidance is cut after a recent raise. Peer multiples imply a price about 13% above where it trades. The thesis has broken due to the primary pillar of revenue growth not meeting targets.
Trailing returns as of 2026-09-04. MCK is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering MCK (as of Sep 2026).
Based on 6 Wall Street analysts offering 12-month price targets for MCK in the last 4 months.
Continue this research
Compare MCK with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MCK Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care (broad) — fair value, gap to price, and forward P/E.
Compare the value case
Put MCK next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand Oncology & Multispecialty segment
Significant investment aligns with Oncology segment expansion objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $907.99
The last 12 months of price, then the range of analyst 12-month targets from today’s $907.99.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Expand Oncology & Multispecialty segment
Acquisition aligns with expanding Oncology & Multispecialty segment.
Advances: Expand Oncology & Multispecialty segment
Acquisition supports expansion in Oncology segment.
Advances: Expand Oncology & Multispecialty segment
Increased guidance supports growth in Oncology segment.
Advances: Reaffirm long-term EPS growth targets
Solid earnings support long-term EPS growth targets.
New guidance indicates potential EPS growth challenges.
Advances: Raise EPS guidance for fiscal 2026
Q2 sales exceeding estimates supports EPS guidance for fiscal 2026.
Threatens: Increase share repurchase authorization
CEO share sale raises concerns about capital allocation strategy.